Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivan S F Chan

Showing results (11-20 of 50) with videos related to

Pageof 5
Sort By:
Biometrics|February 19, 2004
Statistical analysis of noninferiority trials with a rate ratio in small-sample matched-pair designsIvan S F Chan, Nian-Sheng Tang, Man-Lai Tang, et al.
Journal of Biopharmaceutical Statistics|March 11, 2011
Handling missing data in vaccine clinical trials for immunogenicity and safety evaluationXiaoming Li, William W B Wang, Guanghan F Liu, et al.
Statistics in Medicine|June 10, 2021
A practical response adaptive block randomization (RABR) design with analytic type I error protectionTianyu Zhan, Lu Cui, Ziqian Geng, et al.
The Pediatric Infectious Disease Journal|June 29, 2007
Immunogenicity of Oka/Merck varicella vaccine in children vaccinated at 12-14 months of age versus 15-23 months of ageJeffrey L Silber, Ivan S F Chan, William W Wang, et al.
Statistics in Medicine|October 31, 2002
Use of statistical models for evaluating antibody response as a correlate of protection against varicellaIvan S F Chan, Shu Li, Holly Matthews, et al.
Journal of Biopharmaceutical Statistics|April 5, 2014
Confidence-interval construction for rate ratio in matched-pair studies with incomplete dataHui-Qiong Li, Ivan S F Chan, Man-Lai Tang, et al.
The Journal of Infectious Diseases|May 15, 2014
Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curvePeter B Gilbert, Erin E Gabriel, Xiaopeng Miao, et al.
Clinical and Vaccine Immunology : CVI|March 6, 2009
Comparison of the levels of immunogenicity and safety of Zostavax in adults 50 to 59 years old and in adults 60 years old or olderSantosh C Sutradhar, William W B Wang, Katia Schlienger, et al.
The Journal of Infectious Diseases|May 20, 2015
Reply to DunningPeter B Gilbert, Erin E Gabriel, Michael G Hudgens, et al.
Clinical and Vaccine Immunology : CVI|July 13, 2012
Varicella-zoster virus-specific enzyme-linked immunospot assay responses and zoster-associated pain in herpes zoster subjectsStephen K Tyring, Jon E Stek, Jeffrey G Smith, et al.
Pageof 5

Showing results (11-20 of 50) with videos related to

Sort By:
Pageof 5
Biometrics|February 19, 2004
Statistical analysis of noninferiority trials with a rate ratio in small-sample matched-pair designsIvan S F Chan, Nian-Sheng Tang, Man-Lai Tang, et al.
Journal of Biopharmaceutical Statistics|March 11, 2011
Handling missing data in vaccine clinical trials for immunogenicity and safety evaluationXiaoming Li, William W B Wang, Guanghan F Liu, et al.
Statistics in Medicine|June 10, 2021
A practical response adaptive block randomization (RABR) design with analytic type I error protectionTianyu Zhan, Lu Cui, Ziqian Geng, et al.
The Pediatric Infectious Disease Journal|June 29, 2007
Immunogenicity of Oka/Merck varicella vaccine in children vaccinated at 12-14 months of age versus 15-23 months of ageJeffrey L Silber, Ivan S F Chan, William W Wang, et al.
Statistics in Medicine|October 31, 2002
Use of statistical models for evaluating antibody response as a correlate of protection against varicellaIvan S F Chan, Shu Li, Holly Matthews, et al.
Journal of Biopharmaceutical Statistics|April 5, 2014
Confidence-interval construction for rate ratio in matched-pair studies with incomplete dataHui-Qiong Li, Ivan S F Chan, Man-Lai Tang, et al.
The Journal of Infectious Diseases|May 15, 2014
Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curvePeter B Gilbert, Erin E Gabriel, Xiaopeng Miao, et al.
Clinical and Vaccine Immunology : CVI|March 6, 2009
Comparison of the levels of immunogenicity and safety of Zostavax in adults 50 to 59 years old and in adults 60 years old or olderSantosh C Sutradhar, William W B Wang, Katia Schlienger, et al.
The Journal of Infectious Diseases|May 20, 2015
Reply to DunningPeter B Gilbert, Erin E Gabriel, Michael G Hudgens, et al.
Clinical and Vaccine Immunology : CVI|July 13, 2012
Varicella-zoster virus-specific enzyme-linked immunospot assay responses and zoster-associated pain in herpes zoster subjectsStephen K Tyring, Jon E Stek, Jeffrey G Smith, et al.
Pageof 5